Results 81 to 90 of about 16,909 (214)

Indolent zygomycosis associated with deferoxamine chelation therapy [PDF]

, 1994
This paper describes a 71-year-old man with myelodysplasia who required multiple transfusions and subsequent deferoxamine chelation therapy and who then developed indolent cutaneous and probable pulmonary infection with Rhizopus species.
Bradley, Suzanne F., Suzanne F. Bradley, Carol A. Kaufffman, Kaufffman, Carol A., G. P. Prokopowicz, Prokopowicz, G. P.   +5 more
core   +1 more source

Sex and Gender Differences in Iron Chelation

Biomedicines
Background/Objectives: In the absence of physiological mechanisms to excrete excessive iron, the administration of iron chelation therapy is necessary.
Sarah Allegra, Stefano Comità, Antonella Roetto, Silvia De Francia   +3 more
doaj   +1 more source

Optimal Hypoxia Mimetic Small Molecules for Enhancing Angiogenic Properties of Stem Cells From Human Exfoliated Deciduous Teeth

International Endodontic Journal, EarlyView.
ABSTRACT Aim Hypoxic preconditioning of cells holds promise for regenerative therapies, yet identifying effective and safe methods for clinical application remains challenging. We aimed to determine optimal hypoxia‐mimetic small molecules (SMs) that stabilize hypoxia‐inducible factor‐1α (HIF‐1α) and their dosages for hypoxic preconditioning in stem ...
Hong Wang, Jiawei Liu, Xintao Yang, Mohamad Koohi‐Moghadam, Shuting Gao, Yuanyuan Han, Dineshi Sewvandi Thalakiriyawa, James Kit Hon Tsoi, Yanqi Yang, Waruna Lakmal Dissanayaka   +9 more
wiley   +1 more source

Induction of embryonal carcinoma cell differentiation by deferoxamine, a potent therapeutic iron chelator

, 1997
We investigated the effects of deferoxamine on the differentiation of embryonal carcinoma F9 cells. Deferoxamine, a widely used therapeutic agent for thalassemia and iron overload, was found to induce F9 cell differentiation and to have some unique ...
Yuko Ido, Keiichi Tanaka, Tanaka, Tetsuya, Ido, Yuko, Muto, Norio, Tanaka, Keiichi, Norio Itoh, Itoh, Norio, Norio Muto, Tetsuya Tanaka   +9 more
core   +1 more source

Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients [PDF]

, 2001
: Introduction: Iron-chelating therapy with deferoxamine in patients with thalassemia major has dramatically improved the prognosis of this disease. However, the limitations of this treatment have stimulated the design of alternative orally active iron ...
Sheikh-Taha, M., Koussa, S., Mourad, F., Fadi Mourad, Ali Taher, Roger Neeman, Marwan Sheikh‐Taha, Suzanne Koussa, Neeman, R., Taher, A., Adlette Inati, Inati, A.   +11 more
core   +1 more source

Association Between Sleep Quality and Oxidative Stress in Postoperative Cardiovascular Patients—A Pilot Study

Journal of Sleep Research, EarlyView.
In 15 postoperative cardiac surgery patients, venous reactive oxygen species (ROS) measured by electron spin resonance (ESR) over 48 h showed no consistent circadian pattern. Higher ROS was associated with lower subjective sleep efficiency and more nocturnal awakenings, but not with other sleep measures.
K. Krawczyk, D. Riemann, E. Schleicher, A. Günther, A. Ayekoi, M. Czerny, J. S. Pooth, T. Böhmerle, B. Feige, J. Sahlmann, F. Beyersdorf   +10 more
wiley   +1 more source

Effect of intravenous Deferoxamine concomitant use with blood transfusion on serum ferritin in thalassemia major patients

, 2017
Background: Subcutaneous Deferoxamineis often not tolerated by patients and its rejection leads to iron overload with its complications. So, other methods with better toleration and reduction of Deferoxamine consumption are necessary.
Amani, Firouz, Araghchin, Samira, Farzaneh, Esmaeil, Fathi, Afshin   +3 more
core   +1 more source

Deferasirox, an oral chelator in the treatment of iron overload

Italian Journal of Medicine, 2013
BACKGROUND Deferasirox is a once-daily oral iron chelator developed for treating iron overload complicating long-term transfusion therapy in patients with diseases such as beta-thalassemia and myelodysplastic syndromes. Iron overload can damage the liver,
I. Portioli
doaj   +1 more source

Chemically Engineered L. reuteri Delivering αPD‐L1 and Gallium Ions via Metal‐Phenolic Networks Potentiate Anti‐Tumor Immunity and Ferroptosis

Advanced Science, Volume 13, Issue 31, 4 June 2026.
A multifaceted chemical strategy, integrating bacterial tropism, metal‐ion interference therapy, and immunotherapy, resulted in significant tumor regression in murine models. A pioneering paradigm for the design of biohybrid materials was established, highlighting how sophisticated chemical engineering of living systems can unlock new avenues for ...
Tingting Zhang, Mengyi Xu, Yan Zhang, Zhiwen Li, Danqing Song, Jing Pang, Ke Li, Yanxiang Wang   +7 more
wiley   +1 more source

Plasmacytoid Dendritic Cells Exhibit High Transferrin Receptor Expression Without Iron Accumulation

European Journal of Immunology, Volume 56, Issue 6, June 2026.
• pDCs are defined by high surface TFRC expression and dynamic iron flux, distinguishing them from conventional dendritic cell subsets. • In the Iron proteome, pDC are enriched for mitochondrial heme and Fe–S proteins but have similar iron storage to cDC. • Iron chelation does not disrupt pDC type‐1 IFN production. ABSTRACT Plasmacytoid dendritic cells
Carrie Corkish, Simon O'Shaughnessy, Claire Lin, Sophia Wugk, Sarah Kenny, Linda Sinclair, Suzanne Cloonan, David Finlay   +7 more
wiley   +1 more source